

Appendix 3Z

Final Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	MMJ PhytoTech Limited
ABN	91 601 236 417

We (the entity) give ASX the following information under listing rule 3.19A.3 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of director	Jason Bednar
Date of last notice	12 December 2017
Date that director ceased to be director	16 March 2018

Part 1 – Director's relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Number & class of securities 1,026,522 Fully Paid Ordinary Shares 1,500,000 Class D Options (\$0.40, 27/07/2018) 500,000 Class E Performance Rights 500,000 Class F Performance Rights 500,000 Class G Performance Rights

+ See chapter 19 for defined terms.

Appendix 3Z Final Director's Interest Notice

Part 2 – Director's relevant interests in securities of which the director is not the registered holder

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interest	Number & class of securities
Note: Provide details of the circumstances giving rise to the relevant interest	

Part 3 – Director's interests in contracts

Detail of contract	Amalgamation Agreement dated 19 May 2015 in relation to the Company's merger with MMJ Bioscience Inc which was completed on 27 July 2015.
Nature of interest	Mr Bednar was the registered holder of 1.73% of the pre-merger issued capital of MMJ Bioscience Inc. Under the terms of the Amalgamation Agreement, Mr Bednar may be entitled to up to 146,646 fully paid ordinary shares in his capacity as a vendor of MMJ Bioscience upon the satisfaction of the last outstanding performance milestone as set out in the Amalgamation Agreement.
Name of registered holder (if issued securities)	N/A
No. and class of securities to which interest relates	Mr Bednar may be entitled to receive up to an additional 146,646 fully paid ordinary shares upon the satisfaction of the last outstanding performance milestone under the Amalgamation Agreement.

+ See chapter 19 for defined terms.